{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:27:33Z","timestamp":1792621653619,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s40273-019-00844-y","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T10:20:27Z","timestamp":1573208427000},"page":"1391-1408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2021-9574","authenticated-orcid":false,"given":"Nasuh C.","family":"B\u00fcy\u00fckkaramikli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen P. M. H.","family":"Rutten-van M\u00f6lken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan L.","family":"Severens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiwenn","family":"Al","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,8]]},"reference":[{"issue":"2","key":"844_CR1","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jval.2014.01.003","volume":"17","author":"JJ Caro","year":"2014","unstructured":"Caro JJ, Eddy DM, Kan H, Kaltz C, Patel B, Eldessouki R, et al. Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health. 2014;17(2):174\u201382.","journal-title":"Value Health."},{"issue":"10","key":"844_CR2","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s40273-014-0186-2","volume":"32","author":"P Tappenden","year":"2014","unstructured":"Tappenden P, Chilcott JB. Avoiding and identifying errors and other threats to the credibility of health economic models. Pharmacoeconomics. 2014;32(10):967\u201379.","journal-title":"Pharmacoeconomics."},{"key":"844_CR3","doi-asserted-by":"crossref","unstructured":"Sargent RG. Verification and validation of simulation models. In: Henderson SG, Biller B, Hsieh M-H, Tew JD, Barton RR (eds) Proceedings of the 2007 Winter simulation conference. Piscataway: Institute of Electrical and Electronic Engineers Inc.; 2007. p. 124\u201337.","DOI":"10.1109\/WSC.2007.4419595"},{"issue":"6","key":"844_CR4","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jval.2012.04.012","volume":"15","author":"DM Eddy","year":"2012","unstructured":"Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB, et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Value Health. 2012;15(6):843\u201350.","journal-title":"Value Health."},{"issue":"4","key":"844_CR5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, Corro-Ramos I, van Voorn GA, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34(4):349\u201361.","journal-title":"Pharmacoeconomics."},{"issue":"7","key":"844_CR6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40273-017-0508-2","volume":"35","author":"EJ Dasbach","year":"2017","unstructured":"Dasbach EJ, Elbasha EH. Verification of decision-analytic models for health economic evaluations: an overview.\u201d. PharmacoEconomics. 2017;35(7):673\u201383.","journal-title":"PharmacoEconomics."},{"issue":"12","key":"844_CR7","first-page":"785","volume":"9","author":"ER Cox","year":"2003","unstructured":"Cox ER, Motheral B, Mager D. Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s). Am J Manag Care. 2003;9(12):785\u201396.","journal-title":"Am J Manag Care."},{"issue":"5","key":"844_CR8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1046\/j.1524-4733.2003.65241.x","volume":"6","author":"T Hammerschmidt","year":"2003","unstructured":"Hammerschmidt T, Goertz A, Wagenpfeil S, Neiss A, Wutzler P, Banz K. Validation of health economic models: the example of EVITA. Value Health. 2003;6(5):551\u20139.","journal-title":"Value Health."},{"issue":"2","key":"844_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/0272989X14544749","volume":"35","author":"P Joranger","year":"2015","unstructured":"Joranger P, Nesbakken A, Hoff G, Sorbye H, Oshaug A, Aas E. Modeling and validating the cost and clinical pathway of colorectal cancer. Med Decis Mak. 2015;35(2):255\u201365.","journal-title":"Med Decis Mak"},{"issue":"6","key":"844_CR10","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jval.2014.07.007","volume":"17","author":"P McEwan","year":"2014","unstructured":"McEwan P, Foos V, Palmer JL, Lamotte M, Lloyd A, Grant D. Validation of the IMS CORE diabetes model. Value Health. 2014;17(6):714\u201324.","journal-title":"Value Health."},{"issue":"10","key":"844_CR11","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40273-017-0534-0","volume":"35","author":"J M\u00f6ller","year":"2017","unstructured":"M\u00f6ller J, Davis S, Stevenson M, Caro JJ. Validation of a DICE simulation against a discrete event simulation implemented entirely in code. PharmacoEconomics. 2017;35(10):1103\u20139.","journal-title":"PharmacoEconomics."},{"issue":"5","key":"844_CR12","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/j.jval.2011.05.010","volume":"14","author":"A Pichon-Riviere","year":"2011","unstructured":"Pichon-Riviere A, Augustovski F, Bardach A, Colantonio L, Latinclen Tobacco Research Group. Development and validation of a microsimulation economic model to evaluate the disease burden associated with smoking and the cost-effectiveness of tobacco control interventions in Latin America. Value Health. 2011;14(5):S51\u20139.","journal-title":"Value Health."},{"issue":"4","key":"844_CR13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1524-4733.2009.00678.x","volume":"13","author":"A Van Gestel","year":"2010","unstructured":"Van Gestel A, Severens JL, Webers CA, Beckers HJ, Jansonius NM, Schouten JS. Modeling complex treatment strategies: construction and validation of a discrete event simulation model for glaucoma. Value Health. 2010;13(4):358\u201367.","journal-title":"Value Health."},{"issue":"8","key":"844_CR14","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3111\/13696998.2013.809352","volume":"16","author":"M Willis","year":"2013","unstructured":"Willis M, Asseburg C, He J. Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM). J Med Econ. 2013;16(8):1007\u201321.","journal-title":"J Med Econ."},{"issue":"3","key":"844_CR15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40273-016-0471-3","volume":"35","author":"M Willis","year":"2017","unstructured":"Willis M, Johansen P, Nilsson A, Asseburg C. Validation of the economic and health outcomes model of type 2 diabetes mellitus (ECHO-T2DM). Pharmacoeconomics. 2017;35(3):375\u201396.","journal-title":"Pharmacoeconomics."},{"issue":"10","key":"844_CR16","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1089\/dia.2014.0304","volume":"17","author":"W Ye","year":"2015","unstructured":"Ye W, Brandle M, Brown MB, Herman WH. The Michigan model for coronary heart disease in type 2 diabetes: development and validation. Diabetes Technol Ther. 2015;17(10):701\u201311.","journal-title":"Diabetes Technol Ther."},{"key":"844_CR17","volume-title":"Secukinumab for ankylosing spondylitis after inadequate response to non-steroidal antiinflammatory drugs or TNF-alpha inhibitors: a Single Technology Assessment","author":"R Wolff","year":"2016","unstructured":"Wolff R, B\u00fcy\u00fckkaramikli N, Al M, Ryder S, Birnie R, Armstrong N, et al. Secukinumab for ankylosing spondylitis after inadequate response to non-steroidal antiinflammatory drugs or TNF-alpha inhibitors: a Single Technology Assessment. York: Kleijnen Systematic Reviews Ltd; 2016."},{"issue":"2","key":"844_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40273-017-0581-6","volume":"36","author":"NC B\u00fcy\u00fckkaramikli","year":"2018","unstructured":"B\u00fcy\u00fckkaramikli NC, de Groot S, Fayter D, Wolff R, Armstrong N, Stirk L, et al. Pomalidomide with dexamethasone for treating relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib: an evidence review group perspective of an NICE single technology appraisal. PharmacoEconomics. 2018;36(2):145\u201359.","journal-title":"PharmacoEconomics."},{"key":"844_CR19","volume-title":"Idelalisib for treating refractory follicular lymphoma: a single technology assessment","author":"R Riemsma","year":"2018","unstructured":"Riemsma R, B\u00fcy\u00fckkaramikli N, Corro Ramos I, Swift SL, Ryder S, Armstrong N, et al. Idelalisib for treating refractory follicular lymphoma: a single technology assessment. York: Kleijnen Systematic Reviews Ltd; 2018."},{"issue":"12","key":"844_CR20","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s40273-017-0528-y","volume":"35","author":"NC B\u00fcy\u00fckkaramikli","year":"2017","unstructured":"B\u00fcy\u00fckkaramikli NC, Blommestein HM, Riemsma R, Armstrong N, Clay FJ, Ross J, et al. Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy: an evidence review group perspective of a NICE single technology appraisal. PharmacoEconomics. 2017;35(12):1211\u201321.","journal-title":"PharmacoEconomics."},{"key":"844_CR21","volume-title":"Glecaprevir-pibrentasvir for treating chronic hepatitis C; a single technology assessment","author":"R Riemsma","year":"2017","unstructured":"Riemsma R, Corro Ramos I, B\u00fcy\u00fckkaramikli N, Fayter D, Armstrong N, Ryder S, et al. Glecaprevir-pibrentasvir for treating chronic hepatitis C; a single technology assessment. York: Kleijnen Systematic Reviews Ltd; 2017."},{"issue":"2","key":"844_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40273-018-0708-4","volume":"37","author":"NC B\u00fcy\u00fckkaramikli","year":"2019","unstructured":"B\u00fcy\u00fckkaramikli NC, de Groot S, Riemsma R, Fayter D, Armstrong N, Portegijs P, et al. Ribociclib with an aromatase inhibitor for previously untreated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer: an Evidence Review Group perspective of a NICE Single Technology Appraisal. PharmacoEconomics. 2019;37(2):141\u201353.","journal-title":"PharmacoEconomics."},{"key":"844_CR23","volume-title":"Software testing","author":"MG Limaye","year":"2009","unstructured":"Limaye MG. Software testing. New York: Tata McGraw-Hill Education; 2009."},{"key":"844_CR24","unstructured":"Hoogendoorn M, Rutten-van M\u00f6lken MPMH, Hoogenveen RT, et al. Working paper: comparing the cost-effectiveness of a wide range of COPD interventions using a stochastic, dynamic, population model for COPD. 2010. Available at: \nhttp:\/\/www.bmg.eur.nl\/fileadmin\/ASSETS\/bmg\/Onderzoek\/Onderzoeksrapporten___Working_Papers\/OR2010.01.pdf\n\n. Accessed 15 Aug 2019."},{"issue":"8","key":"844_CR25","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1136\/thx.2009.131631","volume":"65","author":"M Hoogendoorn","year":"2010","unstructured":"Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van M\u00f6lken MP. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax. 2010;65(8):711\u20138.","journal-title":"Thorax"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00844-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-019-00844-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00844-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T19:31:03Z","timestamp":1604691063000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-019-00844-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["844"],"URL":"https:\/\/doi.org\/10.1007\/s40273-019-00844-y","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"8 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Nasuh C. B\u00fcy\u00fckkaramikli, Maureen P.M.H. Rutten-van M\u00f6lken, Johan L. Severens, and Maiwenn Al have no conflicts of interest that are relevant to the content of this review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}